These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 12991383)
1. [Evaluation of current treatment of prostatic cancer]. BRENDLER H J Urol; 1952 Oct; 68(4):734-43. PubMed ID: 12991383 [No Abstract] [Full Text] [Related]
2. Evaluation of effect of treatment for primary lesions of stage D2 prostatic cancer by means of transrectal ultrasonotomography. Ohe H; Watanabe H; Saitoh M; Pontes JE; Murphy GP Tohoku J Exp Med; 1986 Jul; 149(3):307-16. PubMed ID: 3532424 [TBL] [Abstract][Full Text] [Related]
4. Symposium on prostatic cancer. IV. Treatment of advanced prostatic cancer. BAKER R J Natl Med Assoc; 1955 May; 47(3):155-7. PubMed ID: 14368283 [No Abstract] [Full Text] [Related]
5. Medical management of prostatic cancer: some current questions. Smith PH Eur Urol; 1980; 6(2):65-8. PubMed ID: 6987062 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous prostatic hematoma: an unusual presentation of prostatic cancer. Morlacco A; Guaitoli P; Abbinante M; Crivellaro S Urologia; 2015; 82(2):118-9. PubMed ID: 24474537 [TBL] [Abstract][Full Text] [Related]
7. [Immunochemical analysis of prostatic acid phosphatase. 3. Evaluation of patients with prostatic cancers and cancer of other organs and a comparison with conventional method]. Sakai S; Kato N; Shimazu R; Doi T; Shimizu Y; Kawada Y; Nishiura T; Sawada H Nihon Hinyokika Gakkai Zasshi; 1982 May; 73(5):609-18. PubMed ID: 6184513 [No Abstract] [Full Text] [Related]
8. Comparative evaluation of National Prostatic Cancer Treatment Group and Gleason systems for pathologic grading of primary prostatic cancer. Gaeta JF; Englander LC; Murphy GP Urology; 1986 Apr; 27(4):306-8. PubMed ID: 3962053 [TBL] [Abstract][Full Text] [Related]
9. [Prostatic cancer: role of echography in the diagnosis, evaluation and surveillance]. Fornage B Bull Cancer; 1985; 72(5):442-51. PubMed ID: 2416372 [TBL] [Abstract][Full Text] [Related]
10. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; Williams G Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825 [TBL] [Abstract][Full Text] [Related]
11. [Criteria of evaluation of the immune response in cryosurgical treatment of prostatic cancer]. Chernyshov VP Urol Nefrol (Mosk); 1978; (1):43-8. PubMed ID: 75602 [No Abstract] [Full Text] [Related]
12. An evaluation of prostate specific antigen in prostatic cancer. Guinan P; Bhatti R; Ray P J Urol; 1987 Apr; 137(4):686-9. PubMed ID: 2435927 [TBL] [Abstract][Full Text] [Related]
13. TARTRATE-INHIBITED ACID PHOSPHATASE IN BENIGN PROSTATIC HYPERTROPHY AND IN PROSTATIC CANCER. JACOBSSON K; LANDBERG T Acta Chir Scand; 1964 Apr; 127():415-26. PubMed ID: 14149644 [No Abstract] [Full Text] [Related]
14. [Improved diagnostic evaluation of prostatic neoplasms using radioimmunoassay for prostatic acid phosphatase]. Gaca A; Panitz N Helv Chir Acta; 1981 Aug; 48(3-4):465-6. PubMed ID: 7287485 [TBL] [Abstract][Full Text] [Related]
15. The role of radical surgery in the treatment of prostatic cancer. Salo JO; Rannikko S Ann Med; 1994 Jun; 26(3):147-51. PubMed ID: 8074833 [TBL] [Abstract][Full Text] [Related]
16. [Fibrinolytic activity in patients of prostatic hypertrophy and prostatic cancer]. YONESE Y; ABE T; SATO A; KAZAMA M Nihon Hinyokika Gakkai Zasshi; 1962 Oct; 53():754-70. PubMed ID: 14002644 [No Abstract] [Full Text] [Related]